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reversal of Pdr5p mediated fluconazole resistance
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Background: Resistance to fluconazole, a commonly used azole antifungal, is a challenge for the treatment of
fungal infections. Resistance can be mediated by overexpression of ABC transporters, which promote drug efflux
that requires ATP hydrolysis. The Pdr5p ABC transporter of Saccharomyces cerevisiae is a well-known model used to
study this mechanism of antifungal resistance. The present study investigated the effects of 13 synthetic
compounds on Pdr5p.
Results: Among the tested compounds, four contained a tellurium-butane group and shared structural similarities that
were absent in the other tested compounds: a lateral hydrocarbon chain and an amide group. These four compounds
were capable of inhibiting Pdr5p ATPase activity by more than 90%, they demonstrated IC50 values less than 2 μM and
had an uncompetitive pattern of Pdr5p ATPase activity inhibition. These organotellurides did not demonstrate cytotoxicity
against human erythrocytes or S. cerevisiae mutant strains (a strain that overexpress Pdr5p and a null mutant strain) even
in concentrations above 100 μM. When tested at 100 μM, they could reverse the fluconazole resistance expressed by both
the S. cerevisiae mutant strain that overexpress Pdr5p and a clinical isolate of Candida albicans.
Conclusions: We have identified four organotellurides that are promising candidates for the reversal of drug resistance
mediated by drug efflux pumps. These molecules will act as scaffolds for the development of more efficient and effective
efflux pump inhibitors that can be used in combination therapy with available antifungals.
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The last decades have seen an increase in the immuno-
compromised population for several reasons including as
a result of treatment of malignant diseases, HIV infection,
as well as advances in organ transplantation procedures.
In this scenario opportunistic infections, especially those
caused by fungi, have become a serious public health
problem [1-3]. Candidiasis is the most common fungal
infection among patients with a condition that leads to
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article, unless otherwise stated.Azoles, especially fluconazole, have been commonly
used to treat fungal infections [6]. However, overexpres-
sion of membrane efflux pumps by fungal cells is an im-
portant mechanism that causes azole resistance [7].
Some of these efflux pumps belong to the Pleiotropic
Drug Resistance (PDR) sub-family of ATP-Binding Cas-
sette (ABC) transporters, and they lead to active transport
of drugs using energy derived from ATP hydrolysis [8].
Saccharomyces cerevisiae can express several ABC
transporters, and of these, Pdr5p has been the best stud-
ied [9]. This efflux pump causes the extrusion of several
drugs that are used to treat fungal infections. Also, it ex-
hibits a profile of substrates and inhibitors that is similar
to those of other ABC transporters that are expressed by
pathogenic fungi [10]. These features make Pdrp5 atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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sistance mediated by ABC transporters.
One strategy for overcoming drug resistance mediated
by efflux pumps is the use of compounds that can func-
tion as chemosensitizers. These compounds potentiate
the efficacy of existing azoles, such as fluconazole, by
inhibiting these ABC transporters [11]. Thus, the develop-
ment of novel azole chemosensitizers that increase the po-
tency of these drugs against both sensitive and resistant
fungi may allow the use of previously ineffective antifungal
to treat fungal infections [12]. Some studies have already
reported compounds that are capable of reversing the re-
sistance phenotype, such as D-Octapeptides [12], enniatin
[13], isonitrile [14] and gallic acid derivatives [15].
Recently, interest in organic compounds containing
tellurium (Te) or selenium (Se) has increased and several
studies have been published demonstrating biological
properties for both elements. Despite the relative toxicity
conferred by organic compounds containing tellurium
[16], some studies have shown that these molecules may
have immunomodulatory and anti-inflammatory proper-
ties [17], antioxidant abilities [18], and anti-proliferative
actions against certain tissues [19]. Selenium is a nutri-
tionally essential trace element for mammals. Studies
have shown that some organic compounds derived from
this chalcogenide exhibit antinociceptive, hepatoprotective,
neuroprotective, anti-inflammatory and anti-carcinogenic
properties [20]. Furthermore, some organochalcogenides
containing Te or Se are capable of inhibiting the ATPase
activity of the Na+/K+ ATPase that is present in rat brains
[21] and can inhibit the ATPase activity of P-Glycoprotein
and vinblastine efflux mediated by this neoplasic cell multi-
drug transporter [22]. Finally, Te and Se containing com-
pounds can inhibit the plasma membrane H+-ATPase from
S. cerevisiae [23].
Although several biological properties have already
been described in the literature for chalcogenides and
their derivatives, molecules containing selenium or tel-
lurium with the capacity to reverse efflux pump-
mediated azole resistance have not yet been reported.
We were interested in studying the effects of organic
compounds containing tellurium or selenium on Pdr5p,
which is a well-known experimental model for the study
of fungal resistance mediated by efflux pumps. In this
study, we evaluated 13 synthetic compounds; some of
which contained tellurium (Te) or selenium (Se), and
others that were devoid of both chalcogenides.
Methods
Chemicals
Reagents were purchased from Sigma-USA (ATP-So-
dium) or Tecoland-USA (FK 506-tacrolimus) unless
otherwise stated. All reagents purchased were of highest
available standard.Synthetic compounds used in this study
The compounds listed in Figure 1 were synthesized ac-
cording to procedures that had been previously developed
by our group; synthetic and spectroscopic information
about these compounds can be found in the original pub-
lications [24-27]. All of the compounds were kept in a
desiccator at 4°C, and the stock solutions were prepared
using dimethyl sulfoxide (DMSO) as a solvent.
Strains and culture conditions
In this study, two mutant strains of Saccharomyces cerevi-
siae were used. The first strain AD124567 (Pdr5p+) over-
expresses Pdr5p, while the genes encoding the Pdr3p
regulator and the other five ABC transporters (Yor1p,
Snq2p, Pdr10p, Pdr11p and Ycf1p) have been deleted. The
second one AD1234567 (Pdr5p-) contains deletions of the
same six genes, as well as the gene that encodes the Pdr5p
transporter [28]. The yeast strains were grown in YPD
medium (2% glucose, 1% yeast extract, 2% peptone) at 30°C
with agitation and were harvested in the exponential
phase of growth. One fluconazole resistant strain of Can-
dida albicans, isolated from urine sample, was also used
(approved by Instituto de Estudos em Saúde Coletiva –
IESC/UFRJ – Protocol N° 030/2001). In this case, the
yeast were cultivated in Sabouraud medium (4% glucose
and 1% peptone), at 37°C under agitation (150 rpm).
Preparation of plasma membranes
Yeast plasma membrane isolates from the S. cerevisiae
mutant strain Pdrp5+ and from the null mutant Pdr5p-
were obtained as previously described by Rangel et al.
[15]. The plasma membrane preparations were stored in
liquid nitrogen and thawed immediately prior to use in
the Pdr5p ATPase activity assays.
ATPase activity assay
The effect of the compounds on the ATPase activity of
Pdr5p was quantified by incubating Pdr5p-containing
membranes (0.013 mg/mL final concentration) in a 96-
well plate at 37°C for 60 min in a reaction medium con-
taining 100 mM Tris–HCl (pH 7.5), 4 mM MgCl2,
75 mM KNO3, 7.5 mM NaN3, 0.3 mM ammonium mo-
lybdate and 3 mM ATP in the presence of the synthetic
compounds. After incubation, the reaction was stopped
by the addition of 1% SDS, as described previously by
Dulley [29]. The amount of released inorganic phosphate
(Pi) was measured as previously described by Fiske &
Subbarrow [30]. Preparations containing plasma mem-
branes obtained from the null mutant strain AD1234567
(Pdr5p- membranes) were used as controls. The differ-
ence between the ATPase activity of the Pdr5p + and
Pdr5p- membranes represents the ATPase activity that is
mediated by Pdr5p.
Figure 2 Effect of synthetic compounds on the Pdr5p ATPase activity. Pdr5p-enriched plasma membranes were incubated in the presence
of the synthetic compounds at a concentration of 100 μM. The ATPase activity was measured as described in the Methods. The control bar
represents 100% of the enzymatic activity in the absence of the compounds. The data represents means ± standard error of three independent
experiments are shown, *p < 0.05.
Figure 1 Chemical structures of the synthetic compounds studied.
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Figure 3 Dose response curves of inhibition on Pdr5p ATPase activity by organotellurium compounds. Pdr5p-enriched plasma membranes
were incubated with: (▲) compound 1; (○) compound 2; (■) compound 3; (◊) compound 5. Data represent means ± SE of three independent
experiments. Inset: Double reciprocal plot of compound 1: (▲) 0 μM; (●) 0.5 μM; (■) 1.0 μM; (♦) 2.0 μM. The experiment was performed using 0.5, 1 or
3 mM ATP as a substrate. The data represent means of three independent experiments.
Table 1 The IC50 values of the compounds against the
ATPase activity of Pdr5p
Compounds IC50 (μM)
1 1.14 ± 0.21
2 1.45 ± 0.49
3 1.74 ± 0.91
5 1.48 ± 0.32
The data represent the means ± standard error of three independent experiments.
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This assay was conducted according to Niimi et al. [12].
The effect of the compounds on the growth of both
mutant strains of S.cerevisiae used in this work was de-
termined by microdilution assays using 96-well micro-
plates. The cells were inoculated into YPD medium at a
concentration of 1 × 104 cells per well and incubated at
30°C for 48 h with agitation (150 rpm) in the presence
of different concentrations of the compounds. Controls
were performed using DMSO at a final concentration of
1% to verify the toxicity of the solvent used to solubilize
the compounds. Cell growth was determined using a mi-
croplate reader at 600 nm (Fluostar Optima, BMG Lab-
tech, Offenburg, Germany).
Lytic effect of compounds on human erythrocytes
This assay was conduct as described by Niimi et al. [12].
Human erythrocytes were previously washed three times
and resuspended in phosphate-buffered saline (PBS-
pH 7.2). Red blood cells (final density 0.5%) were then
incubate in the presence of different concentrations of
the synthetic compounds for 60 min at 37°C. After incu-
bation, the cells were pelleted by centrifugation at 3,000 g
for 5 min and aliquots of 100 μL of the supernatant were
transferred to the wells of a microplate. The absorbance ofthe hemoglobin released from the erythrocytes was mea-
sured at 540 nm. A control of 100% hemolysis was per-
formed incubating the cells in the presence of PBS
containing 1% Triton X-100.Evaluation of fluconazole resistance reversion by the
synthetic compounds
The “spot test” was used as a measure of growth as pre-
viously described by Rangel et al. [15]. For S. cerevisiae
strain Pdr5p+, 5 μL samples of fivefold serially diluted
yeast cultures (initially suspended to an OD of 0.1) were
spotted on YPD agar in 6 well sterile polystyrene plates.
They were incubated in the presence of synthetic com-
pounds (100 μM) only or associated with fluconazole at
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and YPD supplemented with: 120 μg/mL fluconazole,
120 μg/mL fluconazole + 0.5% DMSO, 120 μg/mL flu-
conazole + 10 μM FK506. Plates were incubated at 30°C
for 48 h.
In the case of C. albicans, the same methodology was
used, but with some adaptations: 5 μL of a five-fold ser-
ial dilution from a yeast suspension containing 6 × 105
cells/mL was spotted on Sabouraud agar supplemented
with the compounds at 100 μM alone or combined with
fluconazole at 64 μg/mL. The incubation of the six well
plates was carried at 37°C for 48 h.Figure 4 Effect of organotellurides on the growth of S. cerevisiae mut
incubated in different concentrations (inset) of compounds 1, 2, 3 and 5. T
compounds. The data represent the means ± standard error of three indepCheckerboard assay with compounds and fluconazole
using Candida strain from clinical isolate
Candida albicans cells, in exponential growth phase
(2.5 × 103 cells/mL) were incubated in presence of differ-
ent combinations of fluconazole and compound at 37°C
for 48 hours in RPMI 1640 (Sigma) using 96-well plates
under stirring. Cell growth was determined using a plate
reader (Fluostar Optima, BMG Labtech, Germany) at a
wavelength of 600 nm. The MIC value was referred to
concentration capable of causing 80% growth inhibition
(MIC 80). Possible synergism between fluconazole and
tested compounds was determined based on the fractionalant strains (A) AD124567 and (B) AD1234567. The yeast cells were
he control bar represents 100% of growth in the absence any
endent experiments.
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and antagonistic interactions were defined by a FICI
of <0.5, 0.5-4.0 or 4.0 respectively [31].
Statistical analysis
All experiments were performed in triplicate. Data
were presented as mean ± standard error. A probability
level of 5% (p < 0.05) in Student’s t -test was consid-
ered significant.
Results and discussion
ATPase activity
Pdr5p is an ABC transporter and as such the inhibition
of its ATPase activity could significantly affect the efflux
of fluconazole and contribute to the reversal of resist-
ance against this antifungal. Thus, a screening assay was
performed to identify synthetic compounds that could
promote inhibition of ATP hydrolysis catalyzed by Pdr5p
(at 100 μM final concentration).
Of the 13 compounds tested only four (1, 2, 3 and 5)
were capable of inhibiting Pdr5p ATPase activity by
more than 90% (Figure 2). All four compounds con-
tained a butyl-tellurium residue, a lateral hydrocarbon
chain and an amide group, that were absent in the other
tested compounds. This suggests that these chemical
structure could have an important role in the inhibitory
process.
The four active compounds (1, 2, 3 and 5) were se-
lected for further investigation. Dose–response curves
and a double reciprocal plot were performed (Figure 3).
The results confirm that these compounds are strongFigure 5 Hemolytic activity of organotellurides on human erythrocyte
presence of compounds 1, 2, 3 and 5 at different concentrations (inset). Cont
with DMSO 0.8%, and PBS control – added with no compounds. The data repinhibitors of Pdr5p ATPase activity and exhibit IC50
values lower than 2 μM (Table 1). Furthermore, the
double reciprocal plot for compound 1 demonstrated an
uncompetitive pattern of inhibition (Figure 3). Com-
pounds 2, 3 and 5 demonstrated the same mechanism of
inhibition (data not shown).
Until now, there have been no reports in the literature
of organic synthetic compounds containing tellurium
that inhibit Pdr5p ATPase activity. However, many other
molecules, of synthetic or natural origin, also exhibit this
ability. Silva et al. [32] demonstrated that oroidin, a de-
rivative of a compound from a sponge, is able to inhibit
the catalytic activity of this multidrug transporter with
an IC50 of 20 μM. Rangel et al. [15], while studying gallic
acid derivatives, observed that decyl gallate has an IC50
value of 13.5 μM. Both compounds competitively inhibit
the enzyme activity of Pdr5p. Competitive inhibition is a
more common characteristic than the uncompetitive in-
hibition shown by the four organotellurides.
As mentioned by Cannon et al. [11], inhibition of
plasma membrane H+-ATPase activity could contribute
to the reversal of ABC transporter-mediated azole resist-
ance, by depleting the intracellular ATP concentration.
To investigate this, the effects of the four organotellur-
ides (1, 2, 3 and 5) on the plasma membrane H+-ATPase
of S. cerevisiae were evaluated. The organotellurides
leaded a powerful inhibition of the H+-ATPase activity
(more than 90%) and exhibited IC50 values of approxi-
mately 2.7 μM (data not shown). Chan and colleagues
[23] previously demonstrated that Ebselen, a well-known
organoselenium compound, was also able to inhibit thes. A human erythrocyte suspension (0.5%) was incubated in the
rols: The 100% of hemolisys – PBS with Triton 1%; DMSO control – PBS
resent the means ± standard error of three independent experiments.
Figure 6 Evaluation of the reversion of the fluconazole
resistance by the organotellurides. (A) AD124567 strain of
S. cerevisiae: Fluconazole (−): yeast cell growth on YPD solid in
absence of fluconazole. Fluconazole (+): yeast cell growth on YPD
solid medium in presence of fluconazole at 120 μg/mL. Medium
containing FK506 10 μM+ fluconazole 120 μg/mL was used as
positive control. (B) Resistant Candida albicans strain (clinical isolate):
Fluconazole (−): yeast cell growth on Sabouraud solid medium in
absence of fluconazole. Fluconazole (+): yeast cell growth on
Sabouraud solid in presence of fluconazole at 64 μg/mL.
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a dose dependent manner. Ebselen was also shown to be
toxic for S. cerevisiae at a concentration of 10 μM, un-
like the organotellurides investigated in this study.
Effect of the compounds on the growth of Pdr5p+ and
Pdr5p- mutant S. cerevisiae strains
The organotellurides 1, 2, 3 and 5 that inhibited Pdr5p
activity did not affect the growth of the Pdr5p+ strain at
concentrations up to 200 μM (Figure 4A). However, the
growth of the Pdr5p- null mutant was significantly im-
paired after incubation with 200 μM of compound 5
(Figure 4B). This indicates that this compound could work
as substrate and ATPase activity inhibitor of Pdr5p such
as FK506, a classical and potent Pdr5p inhibitor [33].
Evaluation of cytotoxicity against human erythrocytes
The active compounds were tested for their hemolytic
activity on human erythrocytes (Figure 5). As shown in
Figure 5, even at the highest concentration used in this
assay (128 μM) the four compounds promoted the re-
lease of around 4% of erythrocyte hemoglobin. There
was no significant difference between the hemolysis
caused by the compounds and that observed in PBS
(3.5% hemolysis) and DMSO (3.7% hemolysis) controls.
Therefore, all four active compounds showed another a
desirable feature of a compound to reverse fluconazole
resistance that is a low toxicity for a mammal cell line.
Fluconazole resistance reversion by the synthetic
organotellurides
The spot assay shown in Figure 6A demonstrates that
Pdr5p+ strain, which is resistant to fluconazole (MIC =
600 μg/mL), was able to grow on a medium containing
fluconazole at 120 μg/mL as well as in presence of com-
pounds at 100 μM. However, an evident reduction in
growth was observed when this strain was incubated in
presence of fluconazole (120 μg/mL) associated with any
of the four organotellurides (100 μM). Thus, it was pos-
sible to demonstrate that these synthetic compounds
were able to reverse the fluconazole resistance mediated
by Pdr5p in a manner similar to the reversion promoted
by FK506. A control using the Pdr5p- null mutant (flu-
conazole sensitive strain (AD1234567)) was performed
to confirm that the presence of Pdr5p is responsible for
the fluconazole resistance of the AD124567 strain.
The same experiment was performed using a flucona-
zole resistant Candida albicans clinical isolate because
overexpression of efflux pumps is a possible mechanism
of resistance to azoles in this yeast also. However, the
level of expression of the C. albicans ABC transporter
(CaCdr1p) is lower in comparison to the S. cerevisiae
strains used in the present work that were genetically
modified to overexpress the efflux pump (Pdr5p). Thus,
Table 2 Checkerboard assay* using Candida albicans strain
Compound Fluconazole
Compounds MIC (μg/mL) MIC combined (μg/mL) FIC* MIC (μg/mL) MIC combined (μg/mL) FICa FICIb Outcome
1 68.4 4.3 0.063 256 4 0.016 0.079 Synergy
2 70.0 4.4 0.063 256 4 0.016 0.079 Synergy
3 74.4 2.3 0.030 256 4 0.016 0.046 Synergy
5 74.9 2.3 0.031 256 4 0.016 0.047 Synergy
*This assay was done with organotellurides and fluconazole isolated or combined.
MICs were determined by a microdilution technique based on 80% reduction of growth. aFIC = fractional inhibitory concentration; bFICI = fractional inhibitory
concentration index.
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resistance in pathogenic yeast, as resistant C. albicans
from a clinical isolate, with lower concentration of azole
in comparison with AD124567 strain. The C. albicans
clinical isolate was able to grow in presence of fluconazole
at 64 μg/mL (Figure 6B) that is considered as resistant
strain. The active compounds alone (100 μM) did not
affect growth of C. albicans, but when associated with flu-
conazole (64 μg/mL) were able to promote a complete
growth inhibition in comparison with inhibition obtained
in the presence of FK506 (Figure 6B). This data reinforces
the results obtained with S. cerevisiae and provides further
evidence that blocking efflux pumps represents a valid
therapy measure for treatment of resistant fungal strains.
This strategy becomes more evident using the checker-
board assay where compounds and fluconazole were
tested in different concentrations (Table 2). All com-
pounds tested were able to act synergistically with flucon-
azole since they showed FICI values lower than 0.5 [31].
This proves the efficiency of the use of those organotellur-
ides in combination with azoles in reversion of resistance
due to overexpression of efflux pumps in pathogenic fungi
such as C. albicans.
Conclusions
Compounds 1, 2, 3 and 5 are synthetic compounds that
have some similarities. Firstly, all they contain a butyl
tellurium residue, secondly, they have a lateral hydrocar-
bon chain and finally, they all possess an amide group.
All they were able to reverse the fluconazole resistance
mediated by Pdr5p from S. cerevisiae. A likely mechan-
ism for this reversal is the direct inhibition of the
ATPase activity of Pdr5p and the indirect inhibition of
the plasma membrane H+-ATPase.
Furthermore, the compounds could also overcome flu-
conazole resistance expressed by a clinical isolate of
Candida albicans. The reversal of fluconazole resistance
was obtained using 100 μM of the compounds. This
concentration did not demonstrate toxicity against hu-
man erythrocytes or fungal cells. In conclusion, these
compounds could be promising candidates for the rever-
sal of resistance mediated by drug efflux pumps, actsynergistically with fluconazole and could serve as proto-
types for the synthesis of other molecules that could be
capable of inhibiting efflux pumps with greater efficiency.
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